MeSH tree: C04.834.794
A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II ...
Apr 20, 2026
0
6
Dana-Farber Cancer Institute investigators have developed an online, easy-to-use tool that more accurately predicts when a precursor blood condition called smoldering multiple myeloma is likely to turn into active cancer ...
Mar 24, 2026
0
4
The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single-agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM).
Nov 13, 2025
0
23
A new risk assessment score developed by researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital reveals how multiple myeloma, a form of blood cancer, begins ...
May 21, 2025
0
31
A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk SMM carries a higher likelihood ...
Dec 10, 2024
0
24
